EGFR and non-small cell lung carcinoma: Following this, data from NeoADAURA presented in 2025 demonstrated statistically significant improvement in MPR rates with neoadjuvant osimertinib with or without combination chemotherapy (26% and 25%, respectively), compared to the placebo plus chemotherapy arm (2%) in resectable stage II-IIIB EGFR-mutated NSCLC (p < 0.0001) [65].